Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
3. Results
3.1. Unplanned vs. Planned Excision
3.2. Treatment Following Unplanned Excision
3.3. Recurrence and Survival after Unplanned Excision
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Larios, F.; Gonzalez, M.R.; Ruiz-Arellanos, K.; Aquilino, E.S.G.; Pretell-Mazzini, J. Is Unplanned Excision of Soft Tissue Sarcomas Associated with Worse Oncological Outcomes?-A Systematic Review and Meta-Analysis. Cancers 2024, 16, 443. [Google Scholar] [CrossRef] [PubMed]
- Arai, E.; Nishida, Y.; Tsukushi, S.; Wasa, J.; Ishiguro, N. Clinical and treatment outcomes of planned and unplanned excisions of soft tissue sarcomas. Clin. Orthop. Relat. Res. 2010, 468, 3028–3034. [Google Scholar] [CrossRef] [PubMed]
- Sacchetti, F.; Alsina, A.C.; Morganti, R.; Innocenti, M.; Andreani, L.; Muratori, F.; Scoccianti, G.; Totti, F.; Campanacci, D.A.; Capanna, R. Re-excision after unplanned excision of soft tissue sarcoma: A systematic review and metanalysis. The rationale of systematic re-excision. J. Orthop. 2021, 25, 244–251. [Google Scholar] [CrossRef]
- Bonvalot, S.; Levy, A.; Terrier, P.; Tzanis, D.; Bellefqih, S.; Le Cesne, A.; Le Péchoux, C. Primary Extremity Soft Tissue Sarcomas: Does Local Control Impact Survival? Ann. Surg. Oncol. 2017, 24, 194–201. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Sun, W.; Huang, W.; Yan, W.; Wang, H.; Qu, G.; Wang, K.; Qu, X.; Wang, C.; Chen, Y. Optimal timing of re-excision in synovial sarcoma patients: Immediate intervention versus waiting for local recurrence. J. Surg. Oncol. 2023, 128, 1394–1406. [Google Scholar] [CrossRef] [PubMed]
- Decanter, G.; Stoeckle, E.; Honore, C.; Meeus, P.; Mattei, J.C.; Dubray-Longeras, P.; Ferron, G.; Carrere, S.; Causeret, S.; Guilloit, J.M.; et al. Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. Ann. Surg. Oncol. 2019, 26, 3526–3534. [Google Scholar] [CrossRef]
- Zaidi, M.Y.; Ethun, C.G.; Liu, Y.; Poultsides, G.; Howard, J.H.; Mogal, H.; Tseng, J.; Votanopoulos, K.; Fields, R.C.; Cardona, K. The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. J. Surg. Oncol. 2019, 120, 332–339. [Google Scholar] [CrossRef]
- Davis, A.M.; Kandel, R.A.; Wunder, J.S.; Unger, R.; Meer, J.; OSullivan, B.; Catton, C.N.; Bell, R.S. The impact of residual disease on local recurrence in patients treated by initial unplanned resection for soft tissue sarcoma of the extremity. J. Surg. Oncol. 1997, 66, 81–87. [Google Scholar] [CrossRef]
- Yuan, J.; Li, X.; Yu, S. The efficacy of re-excision after unplanned excision for synovial sarcoma. Heliyon 2024, 10, e23437. [Google Scholar] [CrossRef]
- Gazendam, A.M.; Popovic, S.; Munir, S.; Parasu, N.; Wilson, D.; Ghert, M. Synovial Sarcoma: A Clinical Review. Curr. Oncol. 2021, 28, 1909–1920. [Google Scholar] [CrossRef]
- Sultan, I.; Rodriguez-Galindo, C.; Saab, R.; Yasir, S.; Casanova, M.; Ferrari, A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: An analysis of 1268 patients. Cancer 2009, 115, 3537–3547. [Google Scholar] [CrossRef] [PubMed]
- Aytekin, M.N.; Ozturk, R.; Amer, K.; Yapar, A. Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. J. Orthop. Surg. 2020, 28, 2309499020936009. [Google Scholar] [CrossRef] [PubMed]
- Lewis, J.J.; Antonescu, C.R.; Leung, D.H.; Blumberg, D.; Healey, J.H.; Woodruff, J.M.; Brennan, M.F. Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J. Clin. Oncol. 2000, 18, 2087–2094. [Google Scholar] [CrossRef] [PubMed]
- Trassard, M.; Le Doussal, V.; Hacene, K.; Terrier, P.; Ranchere, D.; Guillou, L.; Fiche, M.; Collin, F.; Vilain, M.O.; Bertrand, G.; et al. Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients. J. Clin. Oncol. 2001, 19, 525–534. [Google Scholar] [CrossRef] [PubMed]
- Wilson, D.A.J.; Gazendam, A.; Visgauss, J.; Perrin, D.; Griffin, A.M.; Chung, P.W.; Catton, C.N.; Shultz, D.; Ferguson, P.C.; Wunder, J.S. Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma. Ann. Surg. Oncol. 2020, 27, 2033–2041. [Google Scholar] [CrossRef]
- Post, J.; Houdek, M.; Folpe, A.L.; Kakar, S.K.; Wilke, B.K. A Retrospective Case Series of Synovial Sarcoma of the Upper Extremity. Sarcoma 2019, 2019, 8704936. [Google Scholar] [CrossRef]
- Liang, Y.; Guo, T.H.; Xu, B.S.; Hong, D.C.; Qiu, H.B.; Zhou, Z.W.; Zhang, X. The Impact of Unplanned Excision on the Outcomes of Patients With Soft Tissue Sarcoma of the Trunk and Extremity: A Propensity Score Matching Analysis. Front. Oncol. 2020, 10, 617590. [Google Scholar] [CrossRef]
- Gingrich, A.A.; Marrufo, A.S.; Liu, Y.; Li, C.S.; Darrow, M.A.; Monjazeb, A.M.; Thorpe, S.W.; Canter, R.J. Radiotherapy is Associated With Improved Survival in Patients With Synovial Sarcoma Undergoing Surgery: A National Cancer Database Analysis. J. Surg. Res. 2020, 255, 378–387. [Google Scholar] [CrossRef]
- Naing, K.W.; Monjazeb, A.M.; Li, C.S.; Lee, L.Y.; Yang, A.; Borys, D.; Canter, R.J. Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J. Surg. Oncol. 2015, 111, 158–164. [Google Scholar] [CrossRef]
- Smolle, M.A.; Tunn, P.U.; Goldenitsch, E.; Posch, F.; Szkandera, J.; Bergovec, M.; Liegl-Atzwanger, B.; Leithner, A. The Prognostic Impact of Unplanned Excisions in a Cohort of 728 Soft Tissue Sarcoma Patients: A Multicentre Study. Ann. Surg. Oncol. 2017, 24, 1596–1605. [Google Scholar] [CrossRef]
- Traub, F.; Griffin, A.M.; Wunder, J.S.; Ferguson, P.C. Influence of unplanned excisions on the outcomes of patients with stage III extremity soft-tissue sarcoma. Cancer 2018, 124, 3868–3875. [Google Scholar] [CrossRef] [PubMed]
- Charoenlap, C.; Imanishi, J.; Tanaka, T.; Slavin, J.; Ngan, S.Y.; Chander, S.; Dowsey, M.M.; Goyal, C.; Choong, P.F. Outcomes of unplanned sarcoma excision: Impact of residual disease. Cancer Med. 2016, 5, 980–988. [Google Scholar] [CrossRef] [PubMed]
- Fromm, J.; Klein, A.; Mentrup, F.; Lindner, L.H.; Nachbichler, S.; Holzapfel, B.M.; Goller, S.S.; Knosel, T.; Durr, H.R. Unplanned Resections of Soft Tissue Sarcomas-Necessity of Re-Resection? Cancers 2024, 16, 1851. [Google Scholar] [CrossRef] [PubMed]
- Wallander, K.; Öfverholm, I.; Boye, K.; Tsagkozis, P.; Papakonstantinou, A.; Lin, Y.; Haglund de Flon, F. Sarcoma care in the era of precision medicine. J. Intern. Med. 2023, 294, 690–707. [Google Scholar] [CrossRef]
- Ho, X.D.; Nguyen, H.G.; Trinh, L.H.; Reimann, E.; Prans, E.; Kõks, G.; Maasalu, K.; Le, V.Q.; Nguyen, V.H.; Le, N.T.N.; et al. Analysis of the Expression of Repetitive DNA Elements in Osteosarcoma. Front. Genet. 2017, 8, 193. [Google Scholar] [CrossRef]
- Raquib, A.R.; Hofvander, J.; Ta, M.; Nielsen, T.O. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma. Appl. Immunohistochem. Mol. Morphol. 2022, 30, 531–539. [Google Scholar] [CrossRef]
Unplanned Excision (n = 87) | Planned Excision (n = 144) | |
---|---|---|
Age at diagnosis, mean (range), years | 39 (5–85) | 40 (5–81) |
Females, proportion | 56% | 44% |
Presenting tumor location, n | ||
Extremity | 63 | 84 |
Abdomen | 6 | 12 |
Chest/Intrathoracic | 7 | 40 |
Head/Neck | 8 | 6 |
Paraspinal | 3 | 2 |
Bone involvement, proportion | 5.7% | 10% |
Intraarticular involvement, proportion | 9.0% | 7.60% |
Monophasic subtype, proportion | 67% | 67% |
Tumor maximum dimension, mean (range), cm | 4.8 (0.9–15) | 8.4 (1.7–37) |
Maximum dimension < 5 cm, proportion | 65% | 28% |
Distant metastases on presentation, n (%) | 3 (3.4%) | 18 (13%) |
A. Local Recurrence | B. Development of Metastasis | C. Disease-Specific Mortality | ||||
---|---|---|---|---|---|---|
Risk Factor | Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value |
Age > 55 years | 1.39 (0.45, 4.31) | 0.57 | 0.86 (0.29, 2.52) | 0.78 | 1.10 (0.41, 2.94) | 0.86 |
Male Gender | 0.39 (0.13, 1.21) | 0.10 | 0.83 (0.36, 1.91) | 0.66 | 0.84 (0.37, 1.88) | 0.66 |
Size < 5 cm | 0.88 (0.30, 2.58) | 0.82 | 0.25 (0.10, 0.60) | <0.01 * | 0.15 (0.06, 0.39) | <0.001 * |
Monophasic Subtype | 3.10 (1.18, 8.19) | 0.02 * | 4.45 (1.01, 19.6) | 0.04 * | 4.11 (0.92, 18.2) | 0.06 |
Lesion Location: | ||||||
Extremity | Reference | - | Reference | - | Reference | - |
Abdomen | 7.22 (1.77, 29.4) | 0.01 * | 1.76 (0.39, 7.90) | 0.46 | 2.22 (1.19, 16.0) | 0.03 * |
Chest | 10.2 (2.73, 38.0) | 0.001 * | 3.68 (1.18, 11.5) | 0.03 * | 3.33 (2.15, 19.1) | <0.001 * |
Head/Neck | 2.85 (0.59, 13.8) | 0.19 | 2.43 (0.68, 8.64) | 0.17 | 2.10 (1.00, 11.2) | 0.06 |
Paraspinal | 1.64 (0.86, 12.5) | 0.14 | 6.24 (1.38, 28.3) | 0.02 * | 2.59 (1.64, 35.0) | 0.01* |
Treatment Included: | ||||||
Re-Excision | 0.14 (0.05, 0.38) | <0.001 * | 0.67 (0.23, 1.98) | 0.47 | 0.35 (0.14, 0.88) | 0.03 * |
Radiation Therapy | 0.61 (0.21, 1.79) | 0.37 | 0.31 (0.13, 0.70) | <0.01 * | 0.35 (0.15, 0.79) | 0.01 * |
Chemotherapy | 1.35 (0.51, 3.60) | 0.55 | 2.07 (0.90, 4.80) | 0.90 | 1.73 (0.96, 3.11) | 0.07 |
Residual Tumor on Re-excision | NA ⱡ | - | 8.17 (1.90, 35.2) | <0.01 * | 7.49 (1.67, 33.6) | 0.01 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Broida, S.E.; Arguello, A.M.; Sullivan, M.H.; Robinson, S.I.; Okuno, S.H.; Siontis, B.L.; Ho, T.P.; Rose, P.S.; Xu-Welliver, M.; Houdek, M.T. Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival. Cancers 2024, 16, 3157. https://doi.org/10.3390/cancers16183157
Broida SE, Arguello AM, Sullivan MH, Robinson SI, Okuno SH, Siontis BL, Ho TP, Rose PS, Xu-Welliver M, Houdek MT. Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival. Cancers. 2024; 16(18):3157. https://doi.org/10.3390/cancers16183157
Chicago/Turabian StyleBroida, Samuel E., Alexandra M. Arguello, Mikaela H. Sullivan, Steven I. Robinson, Scott H. Okuno, Brittany L. Siontis, Thanh P. Ho, Peter S. Rose, Meng Xu-Welliver, and Matthew T. Houdek. 2024. "Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival" Cancers 16, no. 18: 3157. https://doi.org/10.3390/cancers16183157
APA StyleBroida, S. E., Arguello, A. M., Sullivan, M. H., Robinson, S. I., Okuno, S. H., Siontis, B. L., Ho, T. P., Rose, P. S., Xu-Welliver, M., & Houdek, M. T. (2024). Unplanned Excision of Synovial Sarcoma: Factors Associated with Recurrence and Survival. Cancers, 16(18), 3157. https://doi.org/10.3390/cancers16183157